Bio-Techne Corporation (TECH)
Summary
Bio-Techne Corporation (TECH) M&A Call Transcript
Bio-Techne Corporation (TECH) M&A Call Transcript
CMB.TECH: A Stronger Shipping Platform, But Not A Cheap One
CMBT.TECH transformed post-Golden Ocean merger, evolving from a tanker-focused play to a diversified shipping platform with over 250 vessels. Current tanker and dry bulk markets are both robust, driving strong Q1 2026 results, but investors now face multi-cycle risk exposure. Q1 profit of $368.8M was boosted by $267.4M in vessel disposals, reflecting proactive capital management amid favorable market conditions.
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
Bio-Techne Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 215 | $11,887.45 | $15,361.3 | $3,473.85 | 29.22% |
| CE Curtis Ellergodt Rothschild Investment LLC | 18,651 | $982,043.46 | $1.33M | $350,531.32 | 35.69% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 27,125 | $2.56M | $1.94M | -$620,776.13 | -24.26% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $5,881 | $7,144.79 | $1,263.79 | 21.49% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,756 | $93,710.18 | $125,431.08 | $31,720.9 | 33.85% |
Bio-Techne Corporation Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Patrick Donnelly Citigroup | 108.47 | $6,713.78 | $7,753.47 | $1,039.69 | 15.49% |
 Dan Leonard RBC Capital | 57.98 | $3,871.67 | $4,164.45 | $292.78 | 7.56% |
 Brandon Couillard Wells Fargo | 529.63 | $28,926.27 | $38,029.98 | $9,103.71 | 31.47% |
Bio-Techne Corporation (TECH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bio-Techne Corporation ever had a stock split?
Bio-Techne Corporation Profile
| Biotechnology Industry | Healthcare Sector | Mr. Kim Kelderman CEO | NASDAQ (NGS) Exchange | 09073M104 CUSIP |
| BR Country | 3,100 Employees | 29 May 2026 Last Dividend | 30 Nov 2022 Last Split | 9 Feb 1989 IPO Date |
Overview
Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.
Products and Services
Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments:
- Protein Sciences: The cornerstone of Bio-Techne's offerings, this segment focuses on the development and manufacturing of biological reagents critical for life science research, diagnostics, and cell and gene therapy advancements. Products include:
- Cytokines and growth factors: Essential for studying cell signaling and communication.
- Antibodies: Integral for detecting and quantifying target proteins.
- Small molecules: Used in various experimental applications to modulate biological processes.
- Tissue culture sera: Provides a nutritious environment for cell culture growth.
- Cell selection technologies: Enables the isolation of specific cell types for research or therapeutic use.
- Proteomic analytical tools: Includes instruments and immunoassays for protein analysis in biological fluids, facilitating automated western blot and multiplexed ELISA workflows.
- Diagnostics and Genomics: This segment is geared towards the development and manufacture of products for the regulated diagnostics market as well as for research and clinical applications involving genomics and oncology. Offerings include:
- Diagnostic products: Comprising controls, calibrators, and assays for quality assurance in diagnostic testing.
- Exosome-based molecular diagnostic assays: Innovative solutions for detecting disease markers at a molecular level.
- Tissue-based in-situ hybridization assays: Advanced tools for spatial genomic analysis and biopsy examination.
- Genetic and oncology kits: Facilitate research and clinical applications in genetics and cancer diagnostics.
- Carrier screening and oncology diagnostics: Support genetic testing and cancer detection and monitoring.
- Molecular controls: Provide benchmarks for ensuring accuracy in molecular diagnostic tests.
- Process control products: Essential for maintaining quality in hematology, blood chemistry, and coagulation diagnostics.
